[{"id":"c31fe31a-3823-4e8c-81cc-892c70bccfed","acronym":"","url":"https://clinicaltrials.gov/study/NCT07206849","created_at":"2025-10-11T01:31:02.610Z","updated_at":"2025-10-11T01:31:02.610Z","phase":"Phase 2","brief_title":"Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)","source_id_and_acronym":"NCT07206849","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2025-10-03"},{"id":"27333119-b7fd-424a-9cb7-3d186e837736","acronym":"","url":"https://clinicaltrials.gov/study/NCT06965114","created_at":"2025-06-14T13:57:06.110Z","updated_at":"2025-06-14T13:57:06.110Z","phase":"Phase 1/2","brief_title":"Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment","source_id_and_acronym":"NCT06965114","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-11"},{"id":"88ad40d2-3f3c-42ee-9ab2-c0a562d28c8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828069","created_at":"2023-04-25T14:03:34.544Z","updated_at":"2025-02-25T14:09:38.080Z","phase":"Phase 2","brief_title":"A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis","source_id_and_acronym":"NCT05828069","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ERBB3","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ERBB3 mutation","tags":["BRAF • ALK • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ERBB3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"6c2496be-3df0-45cd-80f7-89b122ddc7a0","acronym":"PNOC014","url":"https://clinicaltrials.gov/study/NCT03429803","created_at":"2021-01-18T16:55:07.002Z","updated_at":"2025-02-25T16:59:39.983Z","phase":"Phase 1","brief_title":"DAY101 In Gliomas and Other Tumors","source_id_and_acronym":"NCT03429803 - PNOC014","lead_sponsor":"Karen D. Wright, MD","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/27/2018","start_date":" 02/27/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-03"},{"id":"81eb8371-f87d-49c5-88e5-0d0d26e56e1d","acronym":"VICTORY","url":"https://clinicaltrials.gov/study/NCT06381570","created_at":"2024-04-24T17:31:03.430Z","updated_at":"2024-07-02T16:35:07.877Z","phase":"Phase 1","brief_title":"Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas","source_id_and_acronym":"NCT06381570 - VICTORY","lead_sponsor":"Daniel Morgenstern","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 03/21/2024","start_date":" 03/21/2024","primary_txt":" Primary completion: 03/21/2026","primary_completion_date":" 03/21/2026","study_txt":" Completion: 03/21/2029","study_completion_date":" 03/21/2029","last_update_posted":"2024-04-24"},{"id":"f8142c0b-7e40-45b9-aed0-5a10b17b3a25","acronym":"FIRELIGHT-1","url":"https://clinicaltrials.gov/study/NCT04985604","created_at":"2023-06-26T16:09:30.280Z","updated_at":"2024-07-02T16:35:12.349Z","phase":"Phase 1/2","brief_title":"Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT04985604 - FIRELIGHT-1","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF • NF1 • RAF1","pipe":" | ","alterations":" BRAF fusion • RAF1 amplification","tags":["BRAF • NF1 • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF fusion • RAF1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • pimasertib (AS703026)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-29"},{"id":"46d0f82d-2f23-4a24-969e-e08a45f9ce12","acronym":"","url":"https://clinicaltrials.gov/study/NCT05760586","created_at":"2023-03-08T17:01:50.782Z","updated_at":"2024-07-02T16:35:21.637Z","phase":"","brief_title":"Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma","source_id_and_acronym":"NCT05760586","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-01-31"},{"id":"054476a2-00cc-4fd6-a247-d42447f32989","acronym":"FIREFLY 1","url":"https://clinicaltrials.gov/study/NCT04775485","created_at":"2021-03-01T13:52:29.228Z","updated_at":"2024-07-02T16:35:25.150Z","phase":"Phase 2","brief_title":"A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors","source_id_and_acronym":"NCT04775485 - FIREFLY 1","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/22/2021","start_date":" 04/22/2021","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 06/10/2024","study_completion_date":" 06/10/2024","last_update_posted":"2023-12-27"},{"id":"bb4a6aa4-08e9-4d44-bc20-09c982a16bd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02327169","created_at":"2021-01-18T11:02:33.167Z","updated_at":"2024-07-02T16:36:49.576Z","phase":"Phase 1b","brief_title":"A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies","source_id_and_acronym":"NCT02327169","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation • KRAS exon 2 mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • paclitaxel • irinotecan • sapanisertib (CB-228) • Ojemda (tovorafenib) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 07/02/2018","primary_completion_date":" 07/02/2018","study_txt":" Completion: 07/02/2018","study_completion_date":" 07/02/2018","last_update_posted":"2020-02-25"}]